According to LIXTE Biotechnology Holdings, a biopharmaceutical company, its board of directors has approved a strategic capital allocation plan to allocate up to 25% of its corporate treasury to invest in cryptocurrencies, including Bitcoin and other digital assets. The specific transaction size and timing will be determined based on market conditions and strategic considerations.